Clinical Trial Update: A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness [NA]

View source ↗

Summary

Clinical trial evaluating a single IV dose of motavizumab for RSV illness in infants ≤12 months; study completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection in Infants

Drugs mentioned

• Motavizumab (motavizumab)

Snippet

Sponsor: MedImmune LLC | Conditions: RSV Illness in ≤12 Months of Participants | NA | Status: COMPLETED | Results posted: 2021-08-27